Summer is creeping closer, and for Gilead Sciences that only means one thing: the much-anticipated launch of long-acting HIV ...

Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch ...

Lenacapavir could be a gamechanger in the fight against infection. But US funding cuts have thrown the rollout of the ...

A trial of the influenza antiviral baloxavir suggests that the drug could be used as post-exposure prophylaxis to prevent ...

Despite widespread vaccine availability and improved treatment strategies, certain patients with SARDs remain highly vulnerable to severe COVID-19 outcomes.

Pre-exposure medications and outreach efforts for sex workers, drug users, and vulnerable groups have been stalled.

SPRINGFIELD The Illinois Department of Public Health (IDPH) has issued a standing order that will allow Illinoisans to obtain ...

Data from the last five years show that many people who contracted HIV had seen a provider in the year before.

A company wanted to stop covering PrEP because it "facilitates homosexual behavior." They could upend preventative care for ...

The court will hear the first significant challenge to the Affordable Care Act under the second Trump administration.

The Supreme Court will hear arguments on Monday challenging the constitutionality of a provision in the Affordable Care Act ...

Studies have shown that even as little as $1 in cost can be a disincentive to accessing preventive care, Mason said. "When ...